Biotechnology Companies

AstraZeneca Space Research refers to the ISS-based biologics and cell-therapy research run by AstraZeneca, the pharmaceutical group formed in 1999 from the merger of Sweden's Astra AB and Britain's Zeneca Group, headquartered in Cambridge, UK, listed on the London Stock Exchange, Nasdaq Stockholm and NYSE as AZN, and employing about 89,900 people as of 2025. The company has run several distinct investigations aboard the International Space Station National Laboratory: nanoparticle formation for cancer vaccines, examining how microgravity affects the development of nanoparticles used in therapeutic cancer vaccines; monoclonal antibody production and stability, since these biologic molecules are used to treat cancer and autoimmune disease; and regenerative-medicine work on cell therapies targeting leukemia, breast cancer and glioblastoma. According to the ISS National Lab, AstraZeneca's nanoparticle cancer-vaccine research launched on SpaceX's CRS-17 cargo mission in April 2019, and its monoclonal-antibody stability study launched on SpaceX's CRS-18 mission in July 2019. The company is named by the ISS National Lab alongside Sanofi Pasteur, Merck, Bristol Myers Squibb, Eli Lilly and GlaxoSmithKline as one of several major pharmaceutical companies leveraging microgravity to improve biopharmaceutical manufacturing and drug development. As with the other large drugmakers running similar programs, AstraZeneca's space-based research is one research line within a much larger global pharmaceutical business rather than a separately incorporated company.

Bristol Myers Squibb Space Research refers to the ISS-based drug-development program of Bristol Myers Squibb (BMS), the pharmaceutical group founded in 1887, registered in Princeton, New Jersey, listed on the NYSE as BMY, and employing about 32,500 people as of 2025. BMS studies protein crystallization and alternative drug-delivery methods aboard the International Space Station National Laboratory, with a specific goal of finding ways to replace scheduled medication infusions with quick injections for patients. The company's main ISS research vehicle has been Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) facility, a commercial service provider platform used to examine small-molecule compound crystallization in microgravity. BMS payloads have flown on multiple SpaceX Commercial Resupply Services missions to the station, including CRS-27 in March 2023, continuation supplies on CRS-28 in May 2023, and further work on CRS-31 in November 2024. The company has also run tissue-chip investigations aboard the ISS to gather drug-development insights that are difficult to obtain in terrestrial cell culture. BMS is represented on the ISS National Laboratory's Applied Research and Development Subcommittee, with the company's participation attributed to representatives including Robert Garmise. As with other large drugmakers using the station -- Sanofi, Merck, Eli Lilly, GlaxoSmithKline and AstraZeneca among them -- this space research is a specific, ongoing R&D program rather than a separately incorporated business.

GlaxoSmithKline Space Research refers to the ISS-based biologics research run by GSK plc, the UK pharmaceutical group formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, headquartered in London, listed on the London Stock Exchange as GSK, and employing roughly 65,000 people. GSK studies the stability and aggregation behavior of therapeutic monoclonal antibodies in the microgravity environment of the International Space Station National Laboratory, seeking to better understand the mechanics of protein aggregate formation that can limit a biologic drug's shelf life or effectiveness. The program's co-principal investigators are Dr. Deidre Dalmas Wilk and Dr. Matthew Henry; Dalmas Wilk also sits on the ISS National Lab's Science Subcommittee User Advisory Committee, giving GSK a direct role in shaping station research priorities beyond its own experiments. According to the ISS National Lab, GSK's monoclonal-antibody stability investigations were manifested on the Northrop Grumman CRS-14 cargo mission in September 2020 and the Northrop Grumman CRS-16 mission in August 2021. GSK is named by the ISS National Lab alongside Merck, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Sanofi as one of several major pharmaceutical companies that have moved biologics-stability and drug-development research onto the space station. As with those peers, this is a specific, ongoing research program inside a much larger global pharmaceutical business rather than a standalone company.

Novartis Space Research refers to the ISS-based rodent-physiology program run by the Novartis Institutes of Biomedical Research, the R&D arm of Novartis, the Swiss pharmaceutical group formed in 1996 from the merger of Ciba-Geigy and Sandoz, headquartered in Basel, listed on the SIX Swiss Exchange as NOVN and on the NYSE as NVS (ADS), and employing roughly 75,900 people as of 2024. Novartis's research has focused on muscle wasting (sarcopenia) in microgravity, including work on an implantable device designed to safely administer a muscle-wasting drug over a long period, developed with partners Houston Methodist Research Institute and NanoMedical Systems alongside NASA. The program flew mice to the International Space Station on NASA's Rodent Research-1 (RR-1) mission, which carried five wild-type mice, launched aboard a SpaceX Dragon capsule in September 2014. It continued with Rodent Research-2 (RR-2), led by Dr. Samuel Cadena, which monitored the effects of microgravity on rodent muscle and bone. Results from the first rodent-research mission were published in June 2019, with related publications appearing from 2014 through 2021. The ISS National Lab highlights Novartis as one of the earlier pharmaceutical users of the station's Rodent Research Facility for translational muscle and bone research, a line of work distinct from the protein-crystallization and antibody-stability studies run by pharmaceutical peers such as Merck, Eli Lilly, Sanofi, Bristol Myers Squibb, GlaxoSmithKline and AstraZeneca. It remains a specific research program within Novartis's much larger global pharmaceutical business rather than a separate company.

Sanofi Space Research refers to the ISS-based vaccine research run by Sanofi Pasteur, the vaccines division of French pharmaceutical group Sanofi (founded 1973, headquartered in Paris, listed on Euronext Paris as SAN and Nasdaq as SNY, with roughly 83,000 employees). Sanofi uses BioServe Space Technologies as its implementation partner to fly experiments to the International Space Station National Laboratory studying how the microgravity environment affects vaccine performance. Its documented research includes an 'MDCK Influenza Virus Infection' investigation examining how influenza virus behaves in microgravity, with the goal of informing more effective vaccines, particularly for older adults whose immune response to flu vaccination is typically weaker. According to the ISS National Lab, the project has produced what it described in 2026 as 'unexpected' findings that could help improve vaccine design. Sanofi's ISS research activity is documented from at least 2019 through 2026, and its payloads have flown on ISS cargo resupply missions, including a presence referenced on the SpaceX CRS-21 mission manifest in November 2020. The ISS National Lab lists Sanofi alongside several other large pharmaceutical companies -- including Merck, Eli Lilly, Bristol Myers Squibb, GlaxoSmithKline and AstraZeneca -- as part of a broader wave of drugmakers using the station to study protein behavior, vaccine formulation and drug stability under conditions that cannot be replicated on Earth. As with those peers, the space research is a minor, specific R&D program within a far larger global pharmaceutical business rather than a separate operating company.

Sierra Space Life Sciences

Louisville, United States commercial

Sierra Space Life Sciences is the biotechnology and microgravity research division of Sierra Space, the commercial space company spun out of Sierra Nevada Corporation in 2021 and headquartered in Louisville, Colorado. The division develops turnkey life science research payloads, automated experiment systems, and bio-manufacturing platforms for the International Space Station and Sierra Space's own Orbital Reef commercial space station under development with Boeing and Blue Origin. Microgravity environments unlock biological processes impossible on Earth: protein crystals grown in space have purer, more uniform lattices ideal for drug structure determination; stem cells cultured without gravity's compressive forces can differentiate more rapidly; pharmaceutical compounds that would precipitate or stratify in terrestrial bioreactors can be produced in homogeneous solution. Sierra Space Life Sciences targets these opportunities by providing researchers — pharmaceutical companies, biotech firms, and academic groups — with standardized hardware and on-orbit services that reduce the barrier to ISS-based experiments. The division's payload portfolio includes standardized locker-size experiment modules compatible with ISS EXPRESS Racks and NanoRacks-class carriers, automated fluid handling systems for cell culture experiments requiring minimal crew intervention, and cold-stowage solutions for preserving samples through the return journey. Sierra Space Life Sciences collaborates with ISS National Lab, which allocates the U.S. portion of ISS science to commercial users, to recruit pharmaceutical and biotech clients. Looking forward, Sierra Space Life Sciences is developing the life science infrastructure for Orbital Reef — intended as a commercial LEO destination to replace ISS post-2030. Orbital Reef's design incorporates dedicated microgravity manufacturing modules where continuous bio-manufacturing could produce batch quantities of biologics or stem cells on commercially contracted schedules, rather than the episodic experimental runs possible on ISS. The division competes with Axiom Space's research program, Redwire Space's plant growth systems, and Space Tango's automated ISS laboratory modules for the nascent commercial microgravity research market.

Emulate, Inc. is a Boston biotechnology company, founded in 2014, that makes Organ-Chip technology -- microfluidic devices seeded with living human cells that replicate the function of specific organs for drug testing as an alternative to animal studies. Its product line includes the Brain-Chip, Liver-Chip, Lung-Chip and Kidney-Chip, run on its AVA Emulation System, and the company says its Organ-Chip models have been used across more than 130 scientific publications; its Liver-Chip has been accepted into the FDA's ISTAND pilot program and, according to the company, is the only Organ-Chip cited in the FDA's roadmap for reducing animal testing. Emulate has flown several of its chip platforms to the International Space Station National Laboratory to study how microgravity affects human physiology in ways that are difficult to replicate on Earth, using Zin Technologies as its implementation partner and Space Tango as commercial service provider, with funding support from NIH's National Center for Advancing Translational Sciences (NCATS) and National Institute of Biomedical Imaging and Bioengineering (NIBIB). A Blood-Brain-Barrier Chip investigation launched on SpaceX's CRS-17 mission in April 2019; an Organ-Chips platform investigation flew on CRS-20 in February 2020; and a Brain-Chip study examining the effects of genetic disease launched on CRS-24 in December 2021. The company's ISS work contributed to a patent filed in its 2021 fiscal year for intestinal tissue-chip technology developed to model human enteric physiology, including interactions with the gut microbiome and sensory neurons. The company is privately held, with LinkedIn listing roughly 50-200 employees.

HNu Photonics is an electro-opto-mechanical design and manufacturing company based in Kahului, on Maui, Hawaii, founded in 2006. Alongside defense photonics, specialized optics and renewable-energy work, it develops the Scorpio-V Bio-Chip Space-Lab (BCSL), a compact automated platform that lets academic and industry researchers run long-term cell-culturing experiments with live-cell imaging in microgravity without requiring a crew member to manually tend the cultures. The company flew a Mobile SpaceLab demonstration of the platform to the International Space Station aboard Northrop Grumman's CRS-13 cargo mission in February 2020, with Dr. Caitlin O'Connell-Rodwell as principal investigator, to validate its automated cell-culture and imaging capabilities in orbit. HNu has also received grants to study how microgravity affects neuronal cytoskeletal structure and intracellular trafficking, extending the platform's use into life-sciences research beyond the original validation flight. As of 2024, the ISS National Laboratory listed HNu Photonics among companies with commercial ISS facilities in preparation, indicating planned follow-on hardware beyond the 2020 demonstration. HNu Photonics operates its own CNC machining, optical fabrication and electronics development facilities in-house and serves industrial, research, military, aerospace and university customers. It remains a small, privately held company, with LinkedIn listing roughly 20 employees.

490 BioTech

Boulder, United States commercial

490 BioTech is a Boulder, Colorado biotechnology company founded in 2017 using the unique space environment — specifically microgravity and space radiation — to accelerate beneficial crop genetic mutations for developing climate-resilient seed varieties. The company sends plant seeds to the International Space Station, where the combination of microgravity stress and cosmic radiation exposure causes DNA mutations at significantly higher rates than ground-level mutation breeding, and then screens the resulting mutant plant populations for traits such as drought tolerance, heat resistance, faster growth, and improved nitrogen use efficiency — traits increasingly critical as climate change threatens agricultural productivity in traditional growing regions. This approach is a modern extension of space mutagenesis breeding, a technique pioneered by Soviet and Chinese researchers who flew seeds on early space missions and selected radiation-induced mutants with superior agricultural traits. China's Yuanfeng Agricultural Science has used similar space mutagenesis extensively, producing commercially successful grain varieties. 490 BioTech's value proposition is that space radiation and microgravity create a broader spectrum of mutations than conventional chemical mutagens used in ground-based mutation breeding (EMS, gamma rays), potentially uncovering novel genetic variation not achievable through terrestrial methods. The company works with seed companies and agricultural research institutions to identify high-value mutation targets and conduct post-flight phenotypic and genotypic screening of the resulting mutant populations. Boulder's position in Colorado's agricultural technology cluster, with proximity to USDA Agricultural Research Service stations and Colorado State University's agronomy programs, provides 490 BioTech with collaborator access and agronomic expertise.